

# Contents

|                  |  |          |
|------------------|--|----------|
| <b>Chapter 1</b> | <b>3D Structure and the Drug Discovery Process</b>           | <b>1</b> |
|                  | <i>Roderick E. Hubbard</i>                                   |          |
| 1                | Introduction   | 1        |
| 2                | The Drug Discovery Process                                   | 2        |
| 2.1              | Establishing a Target  | 3        |
| 2.2              | Hit Identification   | 5        |
| 2.3              | Hits to Leads  | 6        |
| 2.4              | Lead Optimisation  | 7        |
| 2.5              | Pre-Clinical Trials  | 8        |
| 2.6              | Clinical Trials  | 8        |
| 2.7              | Maintaining the Pipeline                                     | 9        |
| 3                | What is Structure-Based Drug Discovery?                      | 9        |
| 3.1              | From Hype to Application                                     | 9        |
| 3.2              | Structural Biology   | 10       |
| 3.3              | Structure-Based Design                                       | 11       |
| 3.4              | Structure-Based Discovery                                    | 12       |
| 4                | The Evolution of the Ideas of Structure-Based Drug Discovery | 13       |
| 4.1              | 1960s  | 13       |
| 4.2              | 1970s  | 14       |
| 4.3              | 1980s  | 16       |
| 4.4              | 1990s  | 17       |
| 4.5              | 2000s  | 19       |
| 5                | What isn't in this Book                                      | 20       |
| 5.1              | Drug Discovery Against GPCR Targets                          | 20       |
| 5.2              | Protein-Protein Interactions                                 | 21       |
| 5.3              | Using Structural Models of ADMET Mechanisms                  | 21       |
| 5.4              | Protein Therapeutics   | 22       |
| 5.5              | Other Targets for Structure-Based Drug Discovery             | 22       |
| 6                | Concluding Remarks   | 23       |
|                  | References   | 24       |

|                  |   |           |
|------------------|---|-----------|
| <b>Chapter 2</b> | <b>Structure Determination – Crystallography for Structure-Based Drug Discovery</b> | <b>32</b> |
|                  | <i>David G. Brown and Maria M. Flocco</i>   |           |
| 1                | What is X-ray Crystallography?  | 32        |
| 2                | What is Required to Produce a Crystal Structure?                                    | 35        |
| 3                | Crystallisability of Proteins   | 36        |
| 4                | How does the X-ray Data Relate to the Electron Density? – The Phase Problem         | 36        |
| 5                | Electron Density Map Interpretation and Atomic Model of the Protein                 | 37        |
| 6                | Useful Crystallographic Terminology when Utilising Crystal Structures               | 38        |
| 7                | The Clone-to-Structure Process and SBDD   | 39        |
| 8                | Recent Technological Advances   | 39        |
| 9                | The Role of Crystal Structures in the Discovery Process                             | 42        |
| 10               | The Optimal SBDD System   | 43        |
| 11               | Producing a Biologically Relevant Structure   | 44        |
| 12               | Phosphorylation   | 44        |
| 13               | Glycosylation – Balancing Solubility with Crystallisability                         | 45        |
| 14               | Engineering Solubility  | 46        |
| 15               | Specific Crystal Packing Engineering  | 46        |
| 16               | Engineering Stability   | 47        |
| 17               | Use of Surrogate Proteins   | 47        |
| 18               | The Impact of Structural Genomics   | 48        |
|                  | References  | 49        |
| <b>Chapter 3</b> | <b>Molecular Modelling</b>  | <b>54</b> |
|                  | <i>Xavier Barril and Robert Soliva</i>  |           |
| 1                | Introduction  | 54        |
| 2                | Methods   | 55        |
| 2.1              | Quantum Chemistry Methods   | 55        |
| 2.1.1            | Ligand Internal Energy  | 56        |
| 2.1.2            | Study of Reactivity   | 57        |
| 2.1.3            | Ligand–Receptor Interaction Energy  | 57        |
| 2.2              | Parametric Methods  | 58        |
| 2.2.1            | Force-Fields  | 58        |
| 2.2.2            | Empirical Scoring Functions   | 59        |
| 2.2.3            | Statistical Potentials  | 60        |
| 2.3              | Solvation   | 60        |
| 2.4              | Sampling Algorithms   | 61        |

|       |   |    |
|-------|---|----|
| 3     | Applications                                      | 63 |
| 3.1   | Target Evaluation                                 | 63 |
| 3.1.1 | Target Druggability                               | 64 |
| 3.1.2 | Structure Availability and<br>Critical Assessment | 67 |
| 3.2   | Hit Finding                                       | 69 |
| 3.2.1 | Docking   | 69 |
| 3.2.2 | De novo Design                                    | 72 |
| 3.2.3 | The Role of Chemoinformatics                      | 73 |
| 3.2.4 | Integrative VS                                    | 73 |
| 3.2.5 | Template or Scaffold Hopping                      | 75 |
| 3.2.6 | Target Hopping                                    | 76 |
| 3.3   | Hit to Lead                                       | 77 |
| 3.3.1 | Binding Mode Determination                        | 77 |
| 3.3.2 | Improving the Potency of the Hit                  | 78 |
| 3.3.3 | Modulation of ADMET properties                    | 83 |
| 4     | Conclusion  | 84 |
|       | References  | 85 |

## **Chapter 4 Applications of NMR in Structure-Based Drug Discovery 97**

*Ben Davis and Julia Hubbard*

|       |  |     |
|-------|--|-----|
| 1     | Introduction                                 | 97  |
| 1.1   | The Role of NMR in SBDD                      | 98  |
| 2     | Studying Ligand–Receptor Interactions by NMR | 98  |
| 2.1   | Detecting Ligand Binding                     | 98  |
| 2.2   | Ligand-Based and Receptor-Based<br>Screening | 100 |
| 2.3   | Ligand-Based Approaches                      | 101 |
| 2.3.1 | Filtered Experiments                         | 101 |
| 2.3.2 | Magnetization Transfer Experiments           | 105 |
| 2.3.3 | Fluorine-Detected Experiments                | 112 |
| 2.3.4 | Ligand Displacement by a<br>Known Competitor | 113 |
| 2.4   | Receptor-Based Approaches                    | 114 |
| 2.4.1 | Selective Labeling Strategies                | 115 |
| 2.4.2 | Larger Proteins                              | 116 |
| 2.4.3 | <sup>13</sup> C labeling                     | 117 |
| 2.5   | Examples of NMR-Screening Approaches         | 117 |
| 2.5.1 | Stromelysin                                  | 118 |
| 2.5.2 | Jnk3   | 119 |
| 2.5.3 | DNA Gyrase                                   | 119 |

|       |   |     |
|-------|---|-----|
| 3     | NMR in Structure-Based Lead Optimization                      | 120 |
| 3.1   | Practical Aspects of Ligand–Receptor Complexes                | 121 |
| 3.1.1 | Determining Which NMR Approach to Use                         | 121 |
| 3.1.2 | Methods for Preparation of the Complex                        | 121 |
| 3.2   | NMR Methods for Characterizing Bound Ligands                  | 122 |
| 3.2.1 | NMR Approaches for Ligand–Receptor Complexes in Fast Exchange | 122 |
| 3.2.2 | NMR Approaches for Ligand/Receptor Complexes in Slow Exchange | 127 |
| 3.3   | Chemical-Shift-Based Approaches Combined with Docking         | 129 |
| 4     | Other Applications of NMR in SBDD                             | 131 |
| 4.1   | NMR in Protein Production                                     | 131 |
| 4.2   | Protein Structure Determination by NMR                        | 132 |
| 5     | Conclusion and Outlook  | 132 |
|       | References  | 134 |

## **Chapter 5** **Fragment Screening: An Introduction** **142**

*Andrew R. Leach, Michael M. Hann, Jeremy N. Burrows and Ed Griffen*

|       |  |     |
|-------|--|-----|
| 1     | Introduction   | 142 |
| 2     | The Concept of Drug-Likeness                             | 142 |
| 3     | The Evolution of Lead-Likeness and Fragment Screening    | 144 |
| 4     | Finding Fragments by Screening                           | 154 |
| 4.1   | High Concentration Screening using a Biochemical Assay   | 155 |
| 4.2   | Biophysical and Direct Structure Determination Screening | 155 |
| 4.2.1 | Screening by Crystallography                             | 155 |
| 4.2.2 | Screening by Other Biophysical Methods                   | 156 |
| 5     | The Design of Fragment Screening Sets                    | 156 |
| 6     | Turning Fragment Hits into Leads                         | 161 |
| 6.1   | Fragment Evolution                                       | 162 |
| 6.2   | Fragment Linking   | 163 |
| 6.3   | Fragment Self-Assembly                                   | 165 |
| 6.4   | Fragment Optimisation                                    | 166 |
| 7     | Summary  | 167 |
|       | References   | 169 |

|                  |  |            |
|------------------|--|------------|
| <b>Chapter 6</b> | <b>Iterative Structure-Based Screening of Virtual Chemical Libraries and Factor Xa: Finding the Orally Available Antithrombotic Candidate LY517717</b> | <b>173</b> |
|                  | <i>John W. Liebeschuetz, Stuart D. Jones, Michael R. Wiley and Steven C. Young</i>   |            |
| 1                | Introduction   | 173        |
| 2                | Morphology of the Factor Xa Active Site  | 175        |
| 3                | Structure-Based Library Design   | 176        |
| 4                | Design Strategy for Factor Xa  | 178        |
| 5                | Introducing Oral Availability  | 182        |
| 6                | Non-Basic S1 Series  | 187        |
| 7                | Oral Antithrombotic Activity   | 188        |
| 8                | Conclusion   | 190        |
|                  | Acknowledgements   | 191        |
|                  | References   | 191        |
| <br>             |  |            |
| <b>Chapter 7</b> | <b>Anti-Influenza Drugs from Neuraminidase Inhibitors</b>  | <b>193</b> |
|                  | <i>Peter Colman</i>  |            |
| 1                | Introduction   | 193        |
| 2                | Influenza Viruses  | 193        |
| 3                | Early Attempts to Discover Neuraminidase Inhibitors  | 196        |
| 4                | Neuraminidase Structure  | 196        |
| 5                | Structure-Based Discovery of Inhibitors  | 199        |
|                  | 5.1 Zanamivir  | 199        |
|                  | 5.2 Analogues of Zanamivir   | 200        |
|                  | 5.3 Oseltamivir  | 203        |
|                  | 5.4 BCX1812 (RWJ270201)  | 203        |
|                  | 5.5 A315675  | 205        |
|                  | 5.6 Benzoic Acid Frameworks  | 206        |
| 6                | Retrospective Analyses of Inhibitor-Binding  | 206        |
| 7                | Laboratory Studies of Inhibitor Resistant Variants   | 207        |
| 8                | Clinical Studies of Drug Resistance  | 208        |
| 9                | Drug Profiles  | 209        |
|                  | 9.1 Pharmacology   | 209        |
|                  | 9.2 Efficacy in Therapy  | 210        |
|                  | 9.3 Efficacy in Prophylaxis  | 210        |
|                  | 9.4 Safety   | 211        |
|                  | 9.5 Current Approval Status  | 211        |
| 10               | Conclusions  | 211        |
|                  | References   | 212        |

|                  |  |            |
|------------------|--|------------|
| <b>Chapter 8</b> | <b>Isoform Specificity: The Design of Estrogen Receptor-<math>\beta</math> Selective Compounds</b> | <b>219</b> |
|                  | <i>Eric S. Manas, Richard E. Mewshaw, Heather A. Harris, and Michael S. Malamas</i>                |            |
| 1                | Introduction   | 219        |
| 2                | Structure-Based Design Methodology   | 222        |
| 2.1              | Initial Considerations   | 222        |
| 2.2              | Docking Calculations   | 224        |
| 2.3              | Quantum Chemical Calculations  | 225        |
| 2.4              | Interpretation of Structural Information   | 227        |
| 3                | The Design of Aryl Diphenolic Azoles As ER $\beta$ Selective Agonists                              | 229        |
| 3.1              | Phenyl and Naphthyl Isoxazoles   | 229        |
| 3.2              | Phenyl and Naphthyl Benzoxazoles   | 232        |
| 4                | Learning From and Moving Beyond the Genistein Scaffold   | 236        |
| 4.1              | Biphenyl Scaffolds   | 236        |
| 4.2              | Phenyl Naphthalenes  | 238        |
| 4.3              | Constrained Phenyl-Naphthalene Analogs: Dibenzochromenes   | 244        |
| 5                | Evaluation of ER $\beta$ Selective Compounds in Biological Assays                                  | 245        |
| 6                | Conclusions  | 249        |
|                  | Acknowledgments  | 250        |
|                  | References   | 250        |
|                  | <b>Subject Index</b>   | <b>257</b> |